Astellas Pharmaceuticals Korea Expands Reimbursement Coverage for Prostate Cancer Drug Xtandi
Astellas Pharmaceuticals Korea recently announced that its prostate cancer treatment drug, Xtandi, will now be considered for combination therapy with androgen deprivation therapy (ADT) for patients with metastatic hormone-responsive prostate cancer (mHSPC). This change will take effect this month. Previously, Xtandi + ADT combination therapy was only selectively covered, but now, with the expansion of […]
8% of foreign sales of the top 10 domestic traditional pharmaceutical companies… Japan?
The proportion of foreign sales (exports) of the top 10 traditional pharmaceutical companies in Korea was found to be taking a step back. What was 11% in 2017 has dropped to 8% in the last 2-3 years. The percentage of foreign sales is a barometer that can measure the level of globalization and development of […]
